Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04351373 · ClinicalTrials.gov registry record · Phase 2
Microscopic Fluorescence-guided Vestibular Schwannoma Resection Using Fluorescein Sodium and YELLOW 560
A Phase 2 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT04351373: Completed Phase 2 study, sponsored by Mayo Clinic.
NCT04351373 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04351373, a Phase 2 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to see if there is benefit to using an IV contrast called AK-Fluor® and a microscope filter called YELLOW560 when surgically removing a vestibular schwannoma, Meningioma, Head and Neck Paraganglioma, or Head and Neck Schwannoma.
Interventions
- DRUG Fluorescein Sodium
- DEVICE YELLOW560 filter
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2021-10-06 |
| Est. Completion | 2022-05-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04351373
The ClinicalTrials.gov registry entry for NCT04351373 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Fluorescein Sodium is the first listed.
NCT04351373 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04351373 about?
NCT04351373 is a clinical study titled "Microscopic Fluorescence-guided Vestibular Schwannoma Resection Using Fluorescein Sodium and YELLOW 560". The purpose of this study is to see if there is benefit to using an IV contrast called AK-Fluor® and a microscope filter called YELLOW560 when surgically removing a vestibular schwannoma, Meningioma, Head and Neck Paraganglioma, or Head and Neck Schwannoma.
What is the current status of trial NCT04351373?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2021-10-06. Estimated completion is 2022-05-25.
What interventions are being tested in trial NCT04351373?
The interventions under investigation include: Fluorescein Sodium (DRUG), YELLOW560 filter (DEVICE).
Who is sponsoring clinical trial NCT04351373?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.